Xenetic Biosciences, Inc. (XBIO)

Expanding the Potential of CAR T Cell Therapy

Xenetic Biosciences is a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.

More About Us

Combating Disease Through Innovative Therapies

Product Pipeline

Platform

Personalized CAR T platform targeting cancers with a patient- and tumor-specific approach.

XCART Platform

Transformative Technologies

Our proprietary and patented technologies are being utilized to create life-changing therapies.

Our Novel Technologies

Latest News

May 12, 2021

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

May 10, 2021

Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Investor Presentation

View Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates